TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29778106

Group type: EXPERIMENTAL
Intervention: Topical bromfenac 0.09% twice daily for 2 weeks
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1% 4 times daily with tapering
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Combination of topical bromfenac 0.09% and dexamethasone 0.1%
Number of subjects: 914
Study: 26957853

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 20
Study: 24031025

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (intermittent arm ischaemia through four cycles of 5‐min inflation followed by 5‐min deflation of a blood‐pressure cuff)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control group (primary percutaneous coronary intervention without remote ischaemic conditioning)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 333
Study: 21332853

Group type: EXPERIMENTAL
Intervention: Music delivered by earphones for 20 minutes before surgery
Number of subjects: 183

Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 183
Study: 20021707

Group type: EXPERIMENTAL
Intervention: Personal norms (PN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awareness of adverse consequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascription of responsibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived control over problems
Number of subjects: 0
Study: 18691799

Group type: EXPERIMENTAL
Intervention: Individual BLS refresher training (IT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group refresher training (GT)
Number of subjects: 120
Study: 16076733

Group type: EXPERIMENTAL
Intervention: Bread supplemented with prebiotics and antioxidants
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Faecal water genotoxicity
Number of subjects: 38
Study: 12074764

Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 143
Study: 7668872

Group type: EXPERIMENTAL
Intervention: Chemotherapy with MMC 12 mg/m2 on the day of operation, followed by 6 mg/m2 every two months for 6 times, and FT 800 mg/body/day for one year.
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group with operation only.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Chemotherapy in colon cancer cases with highly positive lymph node metastasis and positive lymphatic vessel invasion.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Chemotherapy in rectal cancer cases, specifically Dukes C cases.
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Chemotherapy in rectal cancer cases with local recurrence, specifically Dukes C and cases of relative curative resection.
Number of subjects: 357
Study: 2913466

Group type: EXPERIMENTAL
Intervention: Hormonal substitutional therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 1570

Group type: EXPERIMENTAL
Intervention: Cordaron
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nonachlasine
Number of subjects: 55
Study: 30873561

Group type: EXPERIMENTAL
Intervention: HAY group (forage included)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CON group (no forage)
Number of subjects: 16
Study: 28880380

Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg sumatriptan nasal powder)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Oral sumatriptan (100 mg tablets)
Number of subjects: 259
Study: 25572140

Group type: EXPERIMENTAL
Intervention: Daptomycin 6 mg/kg IV bolus injection (10 s)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride) IV administration
Number of subjects: 20
Study: 23411098

Group type: EXPERIMENTAL
Intervention: 1.8 mm clear corneal incision (CCI) system (Group 1, Stellaris system)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2.2 mm CCI system (Group 2, Intrepid Infiniti system)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 day postoperative evaluation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1 week postoperative evaluation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3 months postoperative evaluation
Number of subjects: 100
Study: 20131073

Group type: EXPERIMENTAL
Intervention: High intensity diode laser adjunct to root scaling and planing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Root scaling and planing (Control)
Number of subjects: 27
Study: 19474649

Group type: EXPERIMENTAL
Intervention: Incident HSV‐2 infection
Number of subjects: 6396

Group type: EXPERIMENTAL
Intervention: Chronic HSV‐2 infection
Number of subjects: 6396

Group type: EXPERIMENTAL
Intervention: Genital ulcer disease
Number of subjects: 6396

Group type: EXPERIMENTAL
Intervention: Urethral discharge
Number of subjects: 6396

Group type: EXPERIMENTAL
Intervention: Genital washing after intercourse
Number of subjects: 6396

Group type: EXPERIMENTAL
Intervention: Being unmarried
Number of subjects: 6396

Group type: EXPERIMENTAL
Intervention: Being uncircumcised
Number of subjects: 6396

Group type: EXPERIMENTAL
Intervention: Both HIV and HSV‐2 acquisition
Number of subjects: 6396
Study: 17893003

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 2948
Study: 15328329

Group type: EXPERIMENTAL
Intervention: List of Head Start telephone contacts and a computer‐generated packet containing a physician referral letter
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 246
Study: 11165589

Group type: EXPERIMENTAL
Intervention: Para-aortic drainage
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 80
Study: 9973801

Group type: EXPERIMENTAL
Intervention: Oxatomide (1 mg/kg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8152760

Group type: EXPERIMENTAL
Intervention: Dipivefrin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Naphazoline
Number of subjects: 33

Group type: COMPARATOR
Intervention: NaCl solution (0.9%)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dipivefrin, naphazoline, and 0.9% NaCl
Number of subjects: 33
Study: 3370632

Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A per week for 6 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 54
Study: 338255

Group type: EXPERIMENTAL
Intervention: feprazone (600 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: ibuprofen (1200 mg/day)
Number of subjects: 21
Study: 31941539

Group type: EXPERIMENTAL
Intervention: OWise Breast Cancer mobile application for self‐monitoring symptoms and managing care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard care plus OWise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 30515992

Group type: EXPERIMENTAL
Intervention: RePace
Number of subjects: 28

Group type: COMPARATOR
Intervention: DUC
Number of subjects: 28
Study: 28619778

Group type: EXPERIMENTAL
Intervention: Incorporating objectively recorded adherence from the Inhaler Compliance Assessment (INCA) device and lung function into clinical decision making.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard inhaler and adherence education (Control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active group using adherence data and clinical decision protocol.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the INCA device intervention.
Number of subjects: 0
Study: 26431977

Group type: EXPERIMENTAL
Intervention: PACT (100 μg mL(‐1) TBO followed by 94J cm(‐2) LED irradiation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-PACT control
Number of subjects: 45
Study: 23512869

Group type: EXPERIMENTAL
Intervention: Dietary Intake Monitoring Application (DIMA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Daily Activity Monitor Application (DAMA)
Number of subjects: 44
Study: 23258380

Group type: EXPERIMENTAL
Intervention: Standard cold‐light bleaching procedure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bleaching agent
Number of subjects: 12

Group type: COMPARATOR
Intervention: Peroxide‐free bleaching agent
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cold‐light
Number of subjects: 12
Study: 20390807

Group type: EXPERIMENTAL
Intervention: Combined parent-child/family therapy treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cognitive-behavioral individual child treatments
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individual child treatments
Number of subjects: 48
Study: 17712672

Group type: EXPERIMENTAL
Intervention: Intratympanic treatment with AM‐111 at a concentration of 0.4 mg/ml or 2 mg/ml
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 11
Study: 16332650

Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (highest quintile)
Number of subjects: 5961

Group type: EXPERIMENTAL
Intervention: Nonsoluble dietary fiber intake (highest quintile)
Number of subjects: 5961

Group type: EXPERIMENTAL
Intervention: Soluble dietary fiber intake
Number of subjects: 5961

Group type: EXPERIMENTAL
Intervention: Fiber from cereals
Number of subjects: 5961

Group type: EXPERIMENTAL
Intervention: Fiber from vegetables
Number of subjects: 5961

Group type: EXPERIMENTAL
Intervention: Fiber from fruit
Number of subjects: 5961

Group type: EXPERIMENTAL
Intervention: Fiber from dried fruit or nuts and seeds
Number of subjects: 5961

Group type: EXPERIMENTAL
Intervention: Fiber from pulses
Number of subjects: 5961
Study: 12389003

Group type: EXPERIMENTAL
Intervention: Nifedipine tablets (10 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nifedipine capsules (10 mg)
Number of subjects: 64
Study: 9665096

Group type: EXPERIMENTAL
Intervention: DHA (4 g/d)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: EPA (4 g/d)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Corn oil (4 g/d, control)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: DHA and EPA (marine oil groups)
Number of subjects: 224
Study: 8073825

Group type: EXPERIMENTAL
Intervention: Tacalcitol ointment (2 micrograms/g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2684111

Group type: EXPERIMENTAL
Intervention: Posterior lip sclerectomies
Number of subjects: 80

Group type: COMPARATOR
Intervention: Trabeculectomies
Number of subjects: 80
Study: 818720

Group type: EXPERIMENTAL
Intervention: Sotalol (320 mg per day, 160 mg twice daily)
Number of subjects: 30
Study: 30189048

Group type: EXPERIMENTAL
Intervention: Myasthenia gravis cohort
Number of subjects: 6478

Group type: EXPERIMENTAL
Intervention: Myasthenia gravis cohort who underwent thymectomy
Number of subjects: 6478
Study: 28929816

Group type: EXPERIMENTAL
Intervention: Adoair® 125 Aerosol, 2 inhalations twice daily for 8 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Adoair® 250 Diskus®, 1 inhalation twice daily for 8 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Both devices (DPI and pMDI)
Number of subjects: 68
Study: 25989968

Group type: EXPERIMENTAL
Intervention: GlideScope (GVL)
Number of subjects: 26
Study: 23368820

Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 U by i.v. drip infusion for 2 hours)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 44
Study: 21629015

Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of psychiatric disorders
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Point prevalence of psychiatric disorders
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Common psychiatric disorders identified
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Comorbidity of psychiatric disorders
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Correlates of mental illness
Number of subjects: 1054
Study: 19465485

Group type: EXPERIMENTAL
Intervention: High-dose octreotide (60 mg/28 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-frequency octreotide (30 mg/21 days)
Number of subjects: 26
Study: 16981257

Group type: EXPERIMENTAL
Intervention: Triple therapy (peginterferon-alpha-2a 180 mug/wk, ribavirin 800-1000 mg/d, amantadine 200 mg/d for 48 wk)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard interferon-alpha-2a (6 MU/d for 4 wk, 3 MU/d for 20 wk, and 3 MU tiw for 24 wk) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d for 48 wk)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 196
Study: 12928466

Group type: EXPERIMENTAL
Intervention: Conventional risk factors (cigarette smoking, diabetes, hyperlipidemia, hypertension)
Number of subjects: 122458

Group type: EXPERIMENTAL
Intervention: Conventional risk factors
Number of subjects: 122458

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 122458
Study: 10950441

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 9165204

Group type: EXPERIMENTAL
Intervention: Rubber tray
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Screening tray
Number of subjects: 1670
Study: 8142675

Group type: EXPERIMENTAL
Intervention: Norfloxacin (200 mg orally, 2 or 4 times daily) + Amphotericin B (200 mg orally, 4 times daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amphotericin B only
Number of subjects: 106
Study: 2878598

Group type: EXPERIMENTAL
Intervention: Once-daily bevantolol (200 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Twice-daily bevantolol (200 mg)
Number of subjects: 21
Study: 30175789

Group type: EXPERIMENTAL
Intervention: Glucosylceramide (GlcCer) derived from torula yeast (Candida utilis), 1.8 mg/d for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Glucosylceramide (GlcCer) derived from torula yeast (Candida utilis)
Number of subjects: 17
Study: 26198617

Group type: EXPERIMENTAL
Intervention: Intrapyloric BTX‐A injection (group I)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No injection (group II)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study: 25099318

Group type: EXPERIMENTAL
Intervention: Oral corticoids (1 mg/kg daily, decreasing by one-third per week for 3 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 22232457

Group type: EXPERIMENTAL
Intervention: Rolling Malaria Indicator Surveys (rMIS)
Number of subjects: 50
Study: 20135139

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bevacizumab administered 7 days before vitrectomy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Bevacizumab administered 20 days before vitrectomy
Number of subjects: 68
Study: 18055815

Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 50
Study: 15811091

Group type: EXPERIMENTAL
Intervention: 8-MOP 0.01% gel plus UVA
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo plus UVA
Number of subjects: 22
Study: 11916547

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m²), Vinorelbine (25 mg/m²), Cisplatin (75 mg/m²) every 3 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Toxicity profile of the treatment
Number of subjects: 31
Study: 10216806

Group type: EXPERIMENTAL
Intervention: Eprosartan (200 mg b.i.d. to 300 mg b.i.d.)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enalapril (5 mg o.d. to 20 mg o.d.)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Eprosartan + Hydrochlorothiazide (HCTZ) (12.5‐25 mg o.d.)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Enalapril + HCTZ (if required)
Number of subjects: 528
Study: 7602359

Group type: COMPARATOR
Intervention: Standard treatment: craniospinal radiotherapy (RT) followed by eight cycles of 1‐(2‐chloro‐ethyl)‐3‐cyclohexylnitrosourea (CCNU), vincristine (VCR), and prednisone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 8-in-1 chemotherapy followed by RT and then eight additional cycles of 8-in-1
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: M0 stage
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: M1-4 stage
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Age 1.5 to 2 years
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: >= 3 years
Number of subjects: 55
Study: 2228353

Group type: EXPERIMENTAL
Intervention: 13C-glucose (G) ingestion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 13C-fructose (F) ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water only (W) ingestion
Number of subjects: 10
Study: 313330

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30269889

Group type: EXPERIMENTAL
Intervention: ROTEM-guided algorithm
Number of subjects: 355

Group type: COMPARATOR
Intervention: Classical-guided algorithm
Number of subjects: 355
Study: 28351830

Group type: EXPERIMENTAL
Intervention: I-DECIDE, a Web-based healthy relationship tool and safety decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26177812

Group type: EXPERIMENTAL
Intervention: Standard Treatment (hygiene and foot-care intervention)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Delayed Treatment (control group)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Standard Treatment
Number of subjects: 680
Study: 23636185

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Anesthetic injection alone (2 mL 1% lignocaine)
Number of subjects: 131
Study: 21289020

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (0.4 mg/0.1 ml)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intravitreal placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Post cataract steroid subgroup (Intravitreal dexamethasone)
Number of subjects: 62
Study: 19661193

Group type: EXPERIMENTAL
Intervention: Baseline CRP levels
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: Baseline fibrinogen levels
Number of subjects: 2312

Group type: EXPERIMENTAL
Intervention: Baseline plasma viscosity
Number of subjects: 2312
Study: 15918296

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with high dose of allergenic extract (Group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with low dose of allergenic extract (Group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (non SIT-treated patients)
Number of subjects: 75
Study: 12816681

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 11783172

Group type: EXPERIMENTAL
Intervention: Xialian Yiyou Capsule (XLYYC)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Lizhu Dele Capsule (Control)
Number of subjects: 226
Study: 8605463

Group type: EXPERIMENTAL
Intervention: Guided self management
Number of subjects: 115

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 115
Study: 1756252

Group type: EXPERIMENTAL
Intervention: Recombinant human factor VIII (BAY w 6240) administered prophylactically three times a week for 4 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Recombinant human factor VIII (BAY w 6240)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Plasma-derived factor VIII preparation (pdFVIII)
Number of subjects: 5
Study: 6806184

Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 45% branched-chain amino acids (BCAAs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amino acid solution with 10% branched-chain amino acids (BCAAs)
Number of subjects: 30
Study: 31913057

Group type: EXPERIMENTAL
Intervention: Count your drinks
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Use a designated driver
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Leave drinking venues at a pre‐determined time
Number of subjects: 2003
Study: 31082943

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the prostate
Number of subjects: 0
Study: 29145308

Group type: EXPERIMENTAL
Intervention: Pentax AWS
Number of subjects: 140

Group type: COMPARATOR
Intervention: McGrath VL
Number of subjects: 140
Study: 25902324

Group type: EXPERIMENTAL
Intervention: Closed-loop anesthesia delivery system (CLADS)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Manual control (propofol infusion titrated manually)
Number of subjects: 242
Study: 24399452

Group type: EXPERIMENTAL
Intervention: Afatinib 20 mg with ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg with ritonavir (simultaneous administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg with ritonavir (timed administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg with rifampicin
Number of subjects: 0
Study: 21998118

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 365
Study: 18853093

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg od)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 17176505

Group type: EXPERIMENTAL
Intervention: twice-daily rTMS (left prefrontal cortex, 10 Hz, 110% intensity, 1500 stimuli per session)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: once-daily rTMS
Number of subjects: 38

Group type: COMPARATOR
Intervention: sham
Number of subjects: 38
Study: 15867115

Group type: COMPARATOR
Intervention: Pediatric Asthma Care Intervention (PACI)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Peer Leader-based Physician Behavior Change Intervention (PLE)
Number of subjects: 638
Study: 12197262

Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride 0.25% (n = 14)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (normal saline injections; n = 8)
Number of subjects: 22
Study: 10099042

Group type: EXPERIMENTAL
Intervention: Bromocriptine (Br)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Metoclopramide (MTC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Domperidone (DOMP)
Number of subjects: 8
Study: 7813493

Group type: EXPERIMENTAL
Intervention: Penicillin 3 x 10(6) U/6 h plus ofloxacin 200 mg twice daily (group A)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate 1 g/6 h plus erythromycin 1 g/8 h (group B)
Number of subjects: 117